ICD-10 Codes: (quick reference as suggestions: C55 malignant neoplasm of uterus, part unspecified; C56.9 malignant neoplasm of unspecified ovary; C18.9 malignant neoplasm of the colon, unspecified; C50.919 malignant neoplasm of unspecified site of female breast; Z80.9 family history of malignant neoplasm, unspecified)
This letter is in regards to my patient and your subscriber, First, Last Name to request full coverage of medically-indicated genetic testing for hereditary gynecologic cancer to be performed by Ambry Genetics Corporation.
Gynecologic cancers (e.g. ovarian and uterine) are thought to have a hereditary component in up to 25% of cases. Evaluating personal and family histories is a major part of hereditary cancer risk assessment. Mutations in multiple genes markedly increase the lifetime risk for gynecologic cancers (such as up to 40% risk for ovarian cancer for women with BRCA1/BRCA2mutations1, and up to 60% risk for uterine cancer for women with Lynch syndrome2). Some of these gene mutations also increase the lifetime risk for other cancers (such as breast, colorectal, sarcomas, brain, thyroid, and prostate).
Significant aspects of my patient’s personal and/or family medical history that suggest a reasonable probability of hereditary gynecologic cancer are below:
Based on this, I am requesting coverage for this test (GYNplus), which analyzes 13 genes associated with hereditary gynecologic cancer (BRCA1, BRCA2, BRIP1, PALB2, PTEN, RAD51C, RAD51D, TP53)and Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2). Due to the history stated above, there is a reasonable probability of detecting a mutation in my patient. The clinical overlap with mutations in the above-mentioned genes makes this multi-gene test the most efficient and cost-effective way to analyze these genes. According to published guidelines, germline genetic testing is warranted.1,2,3
This genetic testing will help estimate my patient’s risk to develop cancer, and will directly impact my patient’s medical management. The genes in this test havepublished clinical practice guidelines to reduce my patient’s risk of developing (and potentially dying of) an advanced stage cancer. An aggressive approach following established screening and management guidelines is indicated in individuals that carry a mutation found by this test. Management options may include1,2,4:
More frequent colonoscopy
Increased breast screening including self-examinations, clinical breast examinations, mammogram, ultrasound, MRI
Breast cancer risk reduction using prophylactic mastectomies and/or chemoprevention
Prostate cancer screening (PSA and DRE)
Avoidance of radiation treatment when possible
Consideration of MRI-based screening/technologies
Due to the cancer risks associated with these mutations and risk-reducing interventions available, this genetic testing is medically indicated. As such, I am ordering this testing as medically necessary and affirm that my patient has provided informed consent for genetic testing.
A positive test result would confirm a genetic diagnosis and/or risk in my patient, and would ensure my patient is being managed appropriately. I am specifying Ambry Genetics Corporation because this laboratory has highly-sensitive and cost-effective testing for hereditary gynecologic cancer, along with a large database of previously tested patients to ensure highly validated, accurate, and informative test interpretation.
I recommend that you support this request for coverage of diagnostic genetic testing for hereditary gynecologic cancer in my patient. Genetic testing can take up to several weeks to complete, and the laboratory will not bill until testing is concluded. Therefore, we are requesting that the authorization be valid for 3 months.
Thank you for your time, and please don’t hesitate to contact me with any questions.
Ordering Clinician Name (Signature Provided on Test Requisition Form)
(MD/DO, Clinical Nurse Specialist, Nurse-Midwives, Nurse Practitioner, Physician Assistant, Genetic Counselor*)
*Authorized clinician requirements vary by state
Test Details CPT codes: 81211x1, 81213x1, 81292x1, 81294x1, 81295x1, 81297x1, 81298x1, 81300x1, 81317x1, 81319x1, 81321x1, 81323x1, 81403x1, 81405x1, 81479x1
Laboratory: Ambry Genetics Corporation (TIN 33-0892453 / NPI 1861568784), a CAP-accredited and CLIA-certified laboratory located at 7 Argonaut, Aliso Viejo, CA 92656
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2017, 09/19/2016.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2016, 09/26/2016.
Lancaster JM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015 Jan;136(1):3-7.
Villani A, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011 Jun;12(6):559-67.